# Lesson 12: Ethics, Equity, Training and the Future of Psychedelic Practice

*Companion-podcast transcript • Sarah & Kiffer*  
*Office Hours episode to listen to after working through the lesson*

---

**Sarah:** In a survey of therapists who worked in a phase two psilocybin trial, eighty-eight percent of those who answered said they had taken a psychedelic at least once.

**Kiffer:** And only thirty-two of the hundred forty-five therapists it was sent to answered, so we don't know the share for all of them. Even so, it says something about who has been doing this work.

**Sarah:** Which raises a question the field hasn't settled. Should having your own psychedelic experience be part of training to become a psychedelic therapist?

**Kiffer:** There's no outcome evidence either way, and Sarah and I don't fully agree on what training programs should do about that.

**Sarah:** Welcome back to Office Hours. I'm Sarah.

**Kiffer:** And I'm Kiffer. Training and accountability run all through Lesson twelve, Ethics, Equity, Training and the Future of Psychedelic Practice, so let's start with a more basic question about who answers for a therapist's conduct.

**Sarah:** Before question one, a short content note, because this part refers to sexual misconduct by a therapist in a clinical trial. If you'd like support, you can call or text nine eight eight, the Suicide Crisis Helpline, at any time. The Hope for Wellness Help Line for Indigenous people is at one eight five five, two four two, three three one zero. And for sexual violence in British Columbia, VictimLinkBC is at one eight hundred, five six three, zero eight zero eight. So, question one. If a patient in British Columbia has a complaint about someone on a psychedelic therapy team, who can actually investigate it?

**Kiffer:** That depends on the person's profession, because Canada has no separate licence for a psychedelic therapist. In British Columbia, the Health Professions and Occupations Act replaced the Health Professions Act on April first, 2026, and six regulatory colleges now regulate twenty-five professions. A college can investigate a complaint, discipline a member and remove a licence. An association can do far less.

**Sarah:** And that gap showed up in the case from the Vancouver trial site that MAPS disclosed in 2019.

**Kiffer:** It did. In 2022, CBC News reported that the therapist at the centre of that case wasn't a licensed psychologist, and that because British Columbia didn't regulate therapists, no official body could investigate his conduct. Lesson nine went through how the other safeguards failed. Whether anyone could investigate depended on which regulator a person answered to, and that therapist answered to none.

**Sarah:** Let's test that on a team.

**Kiffer:** This one is hypothetical. A service in a mid-sized British Columbia city offers psilocybin-assisted therapy through Special Access Program requests. The team has a family physician, who makes the requests; a registered nurse, who monitors vital signs; a registered clinical counsellor with a certificate in psychedelic therapy, who leads preparation and integration and sits in on dosing sessions; and a guide with an online certificate and no professional registration, who stays with patients through every dosing session. For each of them, who could investigate a complaint in October 2026? Take a few seconds, and pause the audio if you'd like more time.

*(Pause)*

**Sarah:** The physician answers to the College of Physicians and Surgeons of BC, and the nurse to the BC College of Nurses and Midwives. The counsellor belongs to a professional association, the BC Association of Clinical Counsellors, which handles complaints about its own members. The College of Health and Care Professionals of BC is set to regulate psychotherapy from November twenty-ninth, 2027, which would bring people who practise it under a college. And the guide answers to no regulator at all. A complaint could go to the service, and to the police if a crime were involved.

**Kiffer:** That's right. Now look at who spends the most time in the room. In the MDMA trials, dosing sessions ran about eight hours. In this team, the two people who sit longest with a patient in an altered state are the two that no college can yet investigate. For clinical trials, Health Canada's 2022 expectations ask that unlicensed team members be directly supervised by a licensed therapist. My own view is that a service outside a trial should hold itself to at least that standard.

**Sarah:** So what do the guide's certificate and the counsellor's certificate actually tell a patient?

**Kiffer:** They tell you what someone studied, and programs differ widely. Oregon sets a minimum curriculum by rule, at least one hundred twenty-eight hours of core instruction and forty hours of practicum. The Michener Institute's program in Toronto ran about one hundred hours, and its applicants had to acknowledge that "standards and regulations for psychedelic psychotherapy do not currently exist in Canada." And no accreditation body for psychedelic training in Canada has been identified.

**Sarah:** And the programs keep changing. Vancouver Island University cancelled its graduate certificate on November twentieth, 2025, and supported continuing students until August thirty-first, 2026. The latest Michener application deadline on record was November first, 2024. And the MAPS Canada School of Psychedelics, launched in May 2023, was still listed on the MAPS Canada website, while its course platform showed an inactive account on October seventeenth, 2026.

**Kiffer:** So every statement about a program needs a date. And a certificate shows training, while a competency is something you observe in practice. Phelps's six competencies from 2017 include empathetic abiding presence, and therapist self-awareness and ethical integrity, which show up under supervision, over time. Which training components change outcomes for patients is still an open question on the field's research agenda.

**Sarah:** Question two goes back to that eighty-eight percent. Here's a question for everyone. Does that figure tell us anything about whether experiential training makes better therapists? Take a few seconds.

*(Pause)*

**Kiffer:** It tells us very little about that. It describes who did the work in one trial, and with only about a fifth of those invited answering, therapists with experience may have been more willing to reply. To learn whether experience helps, you'd compare outcomes for the patients of therapists with and without it. When almost everyone has the experience, there are too few therapists without it for a useful comparison. Villiger's ethical analysis in 2024 found no evidence that a therapist's personal psychedelic experience improves therapeutic effects or reduces harms.

**Sarah:** Okay. Now the part where we disagree.

**Kiffer:** Whether training programs should offer the experience to trainees at all.

**Sarah:** I think lawful programs should offer it as an option, which is roughly where Villiger lands. He concluded that the evidence doesn't justify a requirement, and that because the experience may be valuable and the chance of harm in screened people is low, trainees should have a legal opportunity. Educators at Vancouver Island University add a practical argument. Legal barriers push trainees who want the experience toward underground sources, and offering it in regulated settings could make it safer and more accountable.

**Kiffer:** I agree that no one should be required to do it, partly because a requirement would shut out trainees for whom psychedelics are medically unsuitable. Where I'm more cautious is building it into programs before we know what it does. Those same educators acknowledge that their arguments "remain anecdotal and open to criticism," and they list counter-arguments, including that personal enthusiasm may bias practitioners and researchers. I'd also worry about pressure. An option that most of your cohort takes, in a program whose faculty will assess you, may not feel optional. It's the same consent problem we worry about with patients, applied to trainees.

**Sarah:** That's a fair worry, but waiting for evidence runs in a circle. You can't study experiential training without a lawful way to provide it, and in Canada that way has been a section fifty-six exemption. Nineteen practitioners received one in 2020 for TheraPsil's training program, later requests were refused in 2022, and on June eighteenth, 2025, the Federal Court of Appeal sent the requests of seventy-three practitioners back to the Minister. No public outcome had been found as of October 2026.

**Kiffer:** You're right about the route, and that's where I'd look. A study of experiential training approved as a clinical trial is itself an authorized route, and it could measure whether the experience changes how therapists practise and how their patients do. Meanwhile, programs have used lawful alternatives such as holotropic breathwork, although those states may not closely resemble a particular drug's effects.

**Sarah:** So we're closer than we sounded. I'd make it available sooner than Kiffer would, and we agree on the practical rule. Experiential training is never a requirement. Where it's offered, it's on an authorized route, it's voluntary, with no effect on a trainee's standing, trainees are screened like any participant, and the program records what happens so the field can learn whether it changes practice.

**Kiffer:** I can sign on to that, and it fits the course's position that experiential training stays within authorized routes.

**Sarah:** Question three is about cost. If you multiply the lesson's full course cost, fourteen thousand six hundred dollars under hypothetical costs, by the number needed to treat of four, you get fifty-eight thousand four hundred dollars for each additional person who no longer meets criteria for PTSD. Is that the number a health authority needs?

**Kiffer:** It needs a second look. In MAPP two, the comparison group had the same therapy hours with a placebo, so the number needed to treat of four describes what MDMA added to that therapy. A health authority usually faces a different choice, between funding the new course and funding something it already offers. Let's build that with invented numbers. The new course is the lesson's schedule, eighty-four clinician hours, which at a hypothetical one hundred fifty dollars an hour plus two thousand dollars of other costs comes to fourteen thousand six hundred dollars.

**Sarah:** And the alternative?

**Kiffer:** A hypothetical established trauma-focused therapy, with twelve weekly ninety-minute sessions and one therapist. That's eighteen clinician hours, or two thousand seven hundred dollars, plus five hundred dollars of other costs, for three thousand two hundred dollars in all. Now imagine a hypothetical head-to-head trial in which sixty-five percent of people no longer meet criteria after the new course and forty-five percent after the established therapy. What does each additional good outcome cost if the authority chooses the new course? Take a few seconds.

*(Pause)*

**Sarah:** I'll try it. The difference is sixty-five minus forty-five, which is twenty percentage points, so the number needed to treat is one divided by 0.2, which is five. Then I multiply the full cost by the number needed to treat, as in the calculation I started with. Fourteen thousand six hundred times five is seventy-three thousand dollars for each additional good outcome.

**Kiffer:** Check that a second way before you settle on it. Picture a hundred people treated each way. What does each program cost, and how many good outcomes does each one produce?

**Sarah:** A hundred people on the new course cost one million four hundred sixty thousand dollars and give sixty-five good outcomes. A hundred people on the established therapy cost three hundred twenty thousand dollars and give forty-five. So choosing the new course costs an extra one million one hundred forty thousand dollars for twenty extra good outcomes, which is fifty-seven thousand dollars each. My seventy-three thousand treated the established therapy as if it cost nothing. I should have multiplied the difference in cost, eleven thousand four hundred dollars, by five.

**Kiffer:** Right. The number needed to treat multiplies the difference in cost between the two options, and the full cost stands in for that difference only when the comparison costs nothing. In MAPP two, where both arms had the same therapy, that difference is much smaller than the full cost. Now the harder part. Suppose the established therapy did better than we assumed, with fifty-five percent no longer meeting criteria. What happens?

**Sarah:** The difference falls to ten points, so the number needed to treat doubles to ten, and eleven thousand four hundred times ten is one hundred fourteen thousand dollars. Here, a ten-point change in how well the comparator works doubles the cost of each extra good outcome.

**Kiffer:** Which is why the field's research agenda asks for comparisons with established treatments and for longer follow-up. Without them, any cost per good outcome rests on a guess about the comparator.

**Sarah:** Then there's who pays. If patients pay privately, Oregon gives some evidence of who gets served. Of the clients in 2025 who reported household income, 58.5 percent reported more than ninety-five thousand three hundred seventy-five US dollars.

**Kiffer:** That figure hides a trap. Two thousand eight hundred twenty-five clients answered the income question, and one thousand six hundred fifty-two of them were above that line. Another nine hundred sixty clients answered the income question by declining to give their income. So among the three thousand seven hundred eighty-five who either answered or declined, what share was above the line?

**Sarah:** It depends on the people who declined. If none of them were above it, the share is one thousand six hundred fifty-two divided by three thousand seven hundred eighty-five, about forty-four percent. If all of them were, it's two thousand six hundred twelve divided by three thousand seven hundred eighty-five, about sixty-nine percent. So the share is somewhere between about forty-four and sixty-nine percent, and the word "most" is safe only for the clients who answered.

**Kiffer:** And about two thousand one hundred fifty of the five thousand nine hundred thirty-five clients have no income response at all, so the careful statement is about clients who reported income. Among them, most had household incomes above that line.

**Sarah:** Need looks different. In a Metro Vancouver cohort of marginalized women surveyed in 2016 and 2017, forty-three percent of four hundred eighty-six said they were interested in psychedelic-assisted therapy, and a price like fourteen thousand six hundred dollars would put it out of reach for many of them.

**Kiffer:** I think if public or charitable money pays for this, it should be spent so that access doesn't follow income, and the service should record whom it reaches.

**Sarah:** Private models carry another risk, which is that clinics close.

**Kiffer:** Field Trip is the Canadian example. Its clinic company, split off in August 2022 with twelve locations, reported a net loss of about 29.6 million Canadian dollars in the nine months to December 2022 and received an initial court order for creditor protection on March twenty-second, 2023. One case can't explain a sector. For patients, though, a closure breaks a treatment that depends on continuity from preparation through integration.

**Sarah:** Before question four, another short content note, because this part discusses colonial harm to Indigenous peoples, including the taking of knowledge, ceremonies and plants. You can call or text nine eight eight, the Suicide Crisis Helpline, at any time, and the Hope for Wellness Help Line for Indigenous people is at one eight five five, two four two, three three one zero. Question four. Canada isn't a Party to the Nagoya Protocol. Does that make benefit sharing optional for a Canadian psychedelic service?

**Kiffer:** Legally, the Protocol doesn't bind Canada. It was adopted in 2010, came into force in 2014, and in October 2026 had one hundred forty-three Parties, including Mexico, Brazil and Gabon. Canada and the United States weren't Parties, and Canada hadn't signed it. Celidwen and colleagues, reporting an Indigenous-led consensus in 2023, point out this gap: frameworks like the Protocol don't reach research and practice in countries that aren't Parties.

**Sarah:** So the obligations have to come from somewhere else.

**Kiffer:** From at least two places. One is the eight principles from that consensus. Under intellectual property, the principle of Reparation asks for fair benefit sharing with the communities whose knowledge or resources are used, including reparation where they were taken without consent.

**Sarah:** And the other is the United Nations Declaration on the Rights of Indigenous Peoples. Article thirty-one recognizes Indigenous peoples' right to maintain, control, protect and develop their traditional knowledge, including medicines and knowledge of the properties of fauna and flora. British Columbia's Declaration Act of 2019 requires the province, in consultation and cooperation with Indigenous peoples, to take all measures necessary to make its laws consistent with the Declaration. That binds the province, though, more than a clinic.

**Kiffer:** That's true. A clinic in British Columbia works inside that commitment, and inside a health care system where the In Plain Sight review of 2020 found widespread Indigenous-specific racism. I'd treat benefit sharing and cultural safety as conditions of ethical practice there, whatever the Protocol's legal reach.

**Sarah:** What about a service that uses synthetic psilocybin? It isn't taking any plant.

**Kiffer:** The principles cover knowledge as well as plants. Reverence asks services to acknowledge Indigenous medicine systems as the root of Western psychedelic practice, and Respect asks for relationships first and free, prior and informed consent before Indigenous knowledge is used in new contexts. Those apply whatever the source of the molecule.

**Sarah:** And new compounds raise the same question. Tabernanthalog was engineered from the structure of ibogaine, which is derived from Tabernanthe iboga, a plant central to the Bwiti tradition of Gabon and Cameroon. Its effects on plasticity and drug-seeking were found in rodents and haven't been shown in people, but if a compound like it reached patients, its origins would bear on these principles.

**Kiffer:** And the plants themselves are under pressure. A 2026 commentary whose authors include Sandor Iron Rope, a Lakota ceremonial leader and founding board member of the Indigenous Peyote Conservation Initiative, argues that legalizing sacred plant medicines would reduce criminal penalties faced by Indigenous peoples and could also lead to overharvesting of sacred plants. For practitioners outside these traditions, the implication is restraint. Western services use synthetic or regulated products through lawful routes, and plant medicines and ceremonies stay under the authority of the communities whose practices they are.

**Sarah:** So let's apply the principles. Here's an invented description from a hypothetical service in British Columbia. "Our program honours ancient Indigenous wisdom. Each session opens with a ceremony our guides learned on a retreat abroad. We call our approach Two-Eyed Seeing. Ten percent of our profits go to an Indigenous charity of our choosing." For everyone listening, which principles does this description run into, and what should the service do before it says anything at all? Take a few seconds.

*(Pause)*

**Kiffer:** Each sentence runs into at least one principle. "Ancient Indigenous wisdom" names no people and no relationship. Acting on Reverence would mean stating the Indigenous origins of the practices in wording guided by local Indigenous scholars and communities. A ceremony learned abroad and led by staff is the decontextualized use that Celidwen and colleagues describe as appropriation, and Respect asks for free, prior and informed consent before Indigenous knowledge is used in a new context.

**Sarah:** And the Two-Eyed Seeing line is the problem Elder Albert Marshall warned about. Two-Eyed Seeing was brought to academic work by Mi'kmaw Elders Albert and Murdena Marshall of Eskasoni First Nation, with Cheryl Bartlett. Elder Albert Marshall cautioned that the term can become "mere jargon, trivialized, romanticized, co-opted," which is the risk when a service uses it with no Indigenous knowledge holders involved.

**Kiffer:** The donation sounds generous, and it still falls short, because the service chose the amount and the recipient on its own. Reparation asks for fair benefit sharing, and Restoration puts Indigenous authority first, so the terms are for communities to set. So the first step comes before any wording. The service builds relationships with local First Nations and Indigenous health organizations, follows their direction, drops the ceremony unless partners agree and take part on their own terms, and writes any acknowledgement with them.

**Sarah:** Some of the principles ask more than one service can do alone, though, such as funding Indigenous-led ethics review.

**Kiffer:** They do, and in my view that's a reason for services to work with health authorities and Indigenous organizations as partners. Let's pull it together with three things to take away.

**Sarah:** First, accountability comes from regulation, and a certificate records training. Ask which college, if any, can investigate each person on a team, and put a date on every statement about a training program, because programs open and close.

**Kiffer:** Second, a cost per good outcome depends heavily on its comparator. Multiply the difference in cost between the two options by the number needed to treat, and check how far the answer moves when the comparator's success rate changes.

**Sarah:** And third, a Canadian service still has ethical obligations of benefit sharing and consent, even though Canada isn't a Party to the Nagoya Protocol. They come from the principles of Celidwen and colleagues, which ask services to follow Indigenous direction and to use no ceremony or knowledge without free, prior and informed consent, and from the commitments in the United Nations Declaration and British Columbia's Declaration Act.

**Kiffer:** If you'd like more practice, rework the cost comparison from this episode with a group schedule for the new course, and see how far the cost of each additional good outcome falls when the clinician hours do.

**Sarah:** This is the last episode of the course. Every fact here was checked in October 2026, so check the current status of any approval, program or rule before relying on it. The course's strands carry on in HSCI 402, HSCI 214 and the graduate course.

**Kiffer:** Take care, everyone.

**Sarah:** And thank you for listening all the way through the course.
